首页> 外文期刊>Case Reports in Nephrology >Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome
【24h】

Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome

机译:利妥昔单抗治疗成人发病肾病综合征后的晚期表核蛋白

获取原文
       

摘要

A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.
机译:一个41岁的女性在32岁的时候开发了肾病综合征,并诊断出基于肾活组织检查的最小变化肾病综合征。虽然通过给予泼尼松龙(PSL)和环孢菌素来实现缓解,但肾病综合征复发。她也开始在Rituximab(RTX)上。在RTX处理(R-LON)后,她开发了晚期表核蛋白,并在17天后改善。虽然大多数R-LON病例经历了自发性缓解,但已报告死亡病例。本报告旨在警告R-LON,因为RTX对成人发病肾病综合征的使用预计将来会增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号